J&J/Merck Mevacor Tests Include Subjects With Slightly Elevated Cholesterol
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck is evaluating Merck's Mevacor (lovastatin) as an OTC candidate by testing the prescription cholesterol reducer in subjects with slightly elevated cholesterol levels. The company has not yet filed an application to switch Mevacor to OTC status.
You may also be interested in...
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.